Accelerating Your Success in Antibody Discovery and Engineering
Syngene provides multi-platform antibody discovery and optimization services to drive faster progression from hits to lead candidates.
Tirbanibulin and targeted dermal delivery in topical drug development
Tirbanibulin shows how ADME science, dermal delivery, and topical formulation development turn
skin drugs into real therapies. Read the full Syngene perspective now.
Therapeutics 2.0: Veterinary Oncology and Peptide Conjugates for Companion Animal Health
Explore how peptide conjugates are advancing veterinary oncology and pet therapeutics through targeted drug delivery. Discover emerging approaches today.
Current Toxicology Developments: Advancing Digital Pathology in Predictive, Mechanistic, and Human-Relevant Safety Science
Explore how digital pathology is transforming predictive toxicology and safety assessment. Learn the latest approaches in modern toxicology—read more now.
Your one-stop-shop for XDCs
Syngene offers an integrated bioconjugation platform for XDCs, providing end-to-end support from antibody discovery to GMP manufacturing at up to 1 kg scale. Their expertise covers diverse conjugation technologies, payload and linker chemistry, and advanced analytical and bioassay support. Syngene ensures single-source manufacturing of antibodies, peptides, oligonucleotides, payloads, and linkers, minimizing risk and delays.
Speed vs. quality: balancing timelines in outsourced R&D with GXP compliance
How pharma teams balance speed and GXP compliance in outsourced R&D to deliver predictabletimelines and regulatory-ready outcomes. Explore the approach.
Syngene’s new biologics facility in the U.S.
Our expanded biologics manufacturing facility in Bayview, Maryland marks a strategic step forward in meeting the growing needs of our global customers. The addition of this facility increases Syngene’s total single-use bioreactor capacity to 50,000 liters, featuring 2,000 and 4,000 liters bioreactors designed to deliver economies of scale.
Neutralizing antibody assay for a fully human PD-1 blocking monoclonal antibody
Learn how Syngene’s PD-1 neutralizing antibody bioassay reduced donor variability and drug interference for immunogenicity assessment. Read the full case study today.
Reimagining CROs: Integrated Innovation Partnerships as the Future of Drug Discovery
Eroom’s Law highlights a troubling trend in pharmaceutical R&D: the cost and time required to develop new drugs have been steadily increasing despite technological advances (1). As a result, drug discovery is under constant pressure.
Immunogenicity assay for an RNAi therapeutic (small interfering RNA) on the MSD platform
Syngene’s MSD-based ADA assay enabled sensitive, drug-tolerant immunogenicity assessment for a clinical siRNA therapeutic in regulated studies. Learn more.